Brief: Shuttle Pharma Announces Results Of Pre-Ind Meeting With FDA For Ropidoxuridine Phase Ii Clinical Trial For Patients With Glioblastoma

Shuttle Pharmaceuticals Holdings

25/09/2023 14:09

Sept 25 (Reuters) - Shuttle Pharmaceuticals Holdings Inc
 SHPH.O :
    * SHUTTLE PHARMA ANNOUNCES RESULTS OF PRE-IND MEETING WITH
FDA FOR
ROPIDOXURIDINE PHASE II CLINICAL TRIAL FOR PATIENTS WITH
GLIOBLASTOMA
    * SHUTTLE PHARMACEUTICALS HOLDINGS INC - COMPANY REMAINS ON
TRACK
TO INITIATE CLINICAL TRIAL IN Q4 OF 2023

Source text for Eikon:  ID:nPn1pDZQVa 
Further company coverage:  SHPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))